We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters to the Editor |

Neonatal Risks of Maternal Treatment With Mood Stabilizers

Mark Olfson, MD, MPH; Steven Marcus, PhD
Arch Gen Psychiatry. 2007;64(7):866-867. doi:10.1001/archpsyc.64.7.866-b.
Text Size: A A A
Published online


Several of the drugs used to treat bipolar disorder are known teratogens.1 Maternal treatment with valproate sodium,2 carbamazepine,3 and lithium4 are each associated with an increased risk of major congenital abnormalities.

In their recent study of maternal antidepressant treatment and neonatal outcomes, Oberlander and colleagues5 report that prenatal selective serotonin reuptake inhibitor (SSRI) exposure is associated with an increased risk of neonatal low birth weight and respiratory distress. The authors compare neonates born of mothers who received SSRIs during their pregnancies with those of depressed pregnant women who did not receive antidepressants. Although neither group of women received benzodiazepines or antipsychotic medications during their pregnancy, women treated with mood stabilizers were not excluded from the study. Because pregnant mothers treated with SSRIs are presumably more likely to receive mood stabilizers than those who are not treated with antidepressants, it is possible that in utero exposure to mood stabilizers partially explains the observed association between maternal SSRI treatment and the adverse neonatal outcomes.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.